Xlife Sciences AG Company Description

Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector.

The company’s project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data.

It also engages biotech and therapies medical technology and artificial intelligence adequate risk diversification; medical offers technology project engages in biotech and therapies, medical technology and artificial intelligence.

In addition, the company supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.

Further, its production, research, development of chemical, and pharmaceutical substances and is an active ingredient manufacturer whose products; and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and medical technology relating to kidney diseases; and offers Neuromex, a screening instrument for the early-stage detection of neurodegenerative diseases.

The company was founded in 2019 and is based in Zurich, Switzerland.

Xlife Sciences AG

Country	Switzerland
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	17
CEO	Oliver Baumann

Contact Details

Address: Talacker 35 Zurich, 8001 Switzerland
Phone	41 44 385 84 60
Website	xlifesciences.ch

Stock Details

Ticker Symbol	XLS
Exchange	SIX Swiss Exchange
Fiscal Year	January - December
Reporting Currency	CHF
ISIN Number	CH0461929603
SIC Code	8731

Key Executives

Name	Position
Oliver R. Baumann	Chief Executive Officer and Executive Director
Carl von Halem	Chief Financial Officer
Beat Klaui	Head of Accounting and Taxation
Dr. Alexander Zink	Head of Technology and Innovation
Dr. Frank Ploger	Chief Scientific Officer
Dr. Dennis Fink	Senior Communications and Investor Relations Manager
Christian Faber	Head of Legal and Compliance